Moore DC - Search Results

1

Pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics.

Moore DC, Digiantonio N, Oxencis CJ, Taucher KD. Moore DC, et al. Am J Health Syst Pharm. 2024 Jul 8;81(14):574-582. doi: 10.1093/ajhp/zxae050. Am J Health Syst Pharm. 2024. PMID: 38394329 Review.

2

Transitioning historically inpatient chemotherapy regimens for hematologic malignancies to the ambulatory care setting.

Moore DC, Arnall JR, Plesca DC. Moore DC, et al. Am J Health Syst Pharm. 2018 Nov 15;75(22):1824-1830. doi: 10.2146/ajhp180060. Epub 2018 Aug 21. Am J Health Syst Pharm. 2018. PMID: 30131323 No abstract available.

3

Fostamatinib for the treatment of immune thrombocytopenia in adults.

Moore DC, Gebru T, Muslimani A. Moore DC, et al. Am J Health Syst Pharm. 2019 May 17;76(11):789-794. doi: 10.1093/ajhp/zxz052. Am J Health Syst Pharm. 2019. PMID: 30951590

4

Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.

Hollifield AL, Arnall JR, Moore DC. Hollifield AL, et al. Among authors: moore dc. Am J Health Syst Pharm. 2020 Jul 23;77(15):1201-1207. doi: 10.1093/ajhp/zxaa151. Am J Health Syst Pharm. 2020. PMID: 32588878 Review.

5

New and emerging pharmacotherapies for the management of multiple myeloma.

Moore DC, Oxencis CJ, Shank BR. Moore DC, et al. Am J Health Syst Pharm. 2022 Jul 8;79(14):1137-1145. doi: 10.1093/ajhp/zxac091. Am J Health Syst Pharm. 2022. PMID: 35333922

6

Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.

Morris SA, Moore DC, Musselwhite LW, Lopes KE, Hamilton A, Steuerwald N, Hanson SL, Larck C, Swift K, Smith M, Kadakia KC, Chai S, Hwang JJ, Patel JN. Morris SA, et al. Among authors: moore dc. Am J Health Syst Pharm. 2023 Sep 22;80(19):1342-1349. doi: 10.1093/ajhp/zxad117. Am J Health Syst Pharm. 2023. PMID: 37235983

7

Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey.

Banez MT, Atienza S, Butts A, Derba M, Dicke K, Haverstick K, Heron BB, Cimino SK, Loop MS, Hough S, Merten JA, Moore DC, Shah V, Taucher KD, Zhang JM, Mahmoudjafari Z. Banez MT, et al. Among authors: moore dc. J Oncol Pharm Pract. 2024 Aug 1:10781552241265280. doi: 10.1177/10781552241265280. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 39091073

8

Neutropenia-Associated Outcomes in Patients With Breast Cancer Receiving Myelosuppressive Chemotherapy With Reduced Doses of Pegfilgrastim.

Moore DC, Gebru T, Pellegrino A, Fasan A, Patel J, Ringley JT. Moore DC, et al. J Pharm Pract. 2020 Dec;33(6):779-783. doi: 10.1177/0897190019838374. Epub 2019 Mar 27. J Pharm Pract. 2020. PMID: 30917723

9

Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center.

Moore DC, Gebru T, Plesca D. Moore DC, et al. J Oncol Pharm Pract. 2021 Dec;27(8):1914-1918. doi: 10.1177/1078155220977898. Epub 2020 Dec 9. J Oncol Pharm Pract. 2021. PMID: 33297847

10

New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Moore DC, Peery MR, Tobon KA, Raheem F, Hwang GS, Alhennawi L, Hughes ME. Moore DC, et al. J Oncol Pharm Pract. 2022 Dec;28(8):1848-1858. doi: 10.1177/10781552221096165. Epub 2022 Apr 26. J Oncol Pharm Pract. 2022. PMID: 35469489 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

457 results

Search Page

Filters